Treatment through week 24
NAIL PSORIASIS
In the three subgroups initially randomized to guselkumab, the mean NAPSI improved from 4.4–5.0 at week 0 to 1.7–2.9 at week 24, which paralleled improvements in PASI (22.6–23.1 at week 0; 0.6–5.2 at week 24) and DLQI (14.3–16.0 at week 0; 2.2–5.0 at week 24) at these time points. In the two subgroups initially randomized to adalimumab, mean NAPSI improved from 4.2–4.7 at week 0 to 1.4–2.2 at week 24; correspondingly, improvements were seen in PASI (20.1–22.7 at week 0; 0.6–7.1 at week 24) and DLQI (15.2–15.3 at week 0; 1.8–8.0 at week 24). A similar pattern of improvement was observed when nail psoriasis was assessed using f-PGA, with both guselkumab (2.4–2.7 at week 0; 0.9–1.5 at week 24) and adalimumab (2.4–2.6 at week 0; 0.7–1.2 at week 24).